Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca's Pulmicort Posts $65 Mil. In Nine-Month U.S. Sales

Executive Summary

AstraZeneca's dry powder inhaled asthma therapy Pulmicort Turbuhaler posted nine-month sales of $65 mil. in the U.S., suggesting that the impact of supply constraints imposed by FDA may be beginning to ease, CEO Tom McKillop reported during an Oct. 28 teleconference on third quarter financial results.

You may also be interested in...



AstraZeneca Nexium NDA Includes "On-Demand" Dosing

AstraZeneca's NDA for the Prilosec follow-on product Nexium includes an indication for "on demand" maintenance treatment for gastroesophageal reflux disease.

AstraZeneca Nexium NDA Includes "On-Demand" Dosing

AstraZeneca's NDA for the Prilosec follow-on product Nexium includes an indication for "on demand" maintenance treatment for gastroesophageal reflux disease.

Casodex Prostate Cancer Monotherapy Survival Is Similar To Castration - U.K.

Prostate cancer treatment with AstraZeneca's Casodex (bicalutamide) as monotherapy does not increase mortality risk compared to castration, U.K. labeling for the anti-androgen indicates. The Medicines Control Agency cleared the indication on June 17.

UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel